The third edition of this report provides an overview of the life sciences research tools market from 2009 to 2017. Life sciences research tools companies offer instruments, reagents and services to academic, BioPharma, applied market and (non-IVD) clinical customers. This market is consolidated, with top vendors including Agilent, Bio-Rad, EMD Millipore, Illumina, Life Technologies*, Roche, Sigma-Aldrich and Thermo Fisher representing the majority of sales; however, mid-size players (e.g., Luminex) and smaller emerging players are highlighted and included in this report as well (e.g., Oxford Nanopore, Quanterix, Seahorse Biosciences). As in previous versions, we carefully triangulated market growth with past and forecasted organic growth from keys players, many of which have experienced growth driven by acquisition. As a result, segmenting the market by technology, we estimate that the life science research tools market reached $41.4B in 2013, and is expected to grow ~4% p.a. in the next 4 years. These figures are in contrast with other reports on individual technologies that report bullish growth rates of 5%-20% for many technologies. Our analysis confirm that growth will be gated by academic funding in Western countries growing in low single digits, and expected to continue to represent the majority of funding. With that said, our analysis confirms that applied market (such as non-IVD clinical, forensics or AgBio customers) might experience double digit growth for many technologies. This report evaluates which technologies are expected to capture (e.g., NGS, mass spectrometry) and loose (e.g., PCR, microarrays) relative market share.
In this third edition, we updated our analysis to reflect the most current market sales and trends in 5 broad segments:
1)Pure genomics technologies: qPCR, next generation sequencing (NGS) / third generation sequencing (3GS), microarrays, PCR, CE sequencing, molecular biology tools, digital PCR;
2)Pure proteomics technologies: Antibodies, ELISA, protein production, western blots and protein microarrays;
3)Cell biology technologies: discovery services, microscopy, basic cell biology reagents, flow cytometry, transfection and electroporation, media and sera, cell culture equipment, cells and tissues, whole cell analysis, high content imaging;
4)Other analytical technologies: liquid chromatography, mass spectroscopy, structural analysis methods, in vivo study, spectroscopy, multiplex technologies, label free technologies;
5)Other supplies and technologies: lab supplies and disposables, automation, glassware, sample preparation, LIMS, magnetic beads For each of these 35 subsegments, we present an analysis detailing sales of instruments and reagents for 2009, 2013 and 2017. In addition, we detail market drivers (e.g., adoption of NGS as LDTs in clinical settings) and moderators (e.g., pricing pressure for some technologies), market trends (e.g., interest in single cell analysis), a high level end-customer breakdown (Academic, BioPharma and Applied markets customers) and key competitors.
All data are based on manufacturer sales as publically reported, and a total of 41 interviews with life sciences experts in academic, BioPharma and applied market laboratories conducted in the last 4 months